#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
CS

Hypercholesterolemia as a risk factor for hearing loss: Do we have sufficient evidence?

Czech version

Authors: Zuzana Capová 1;  Lukáš Varga 2,3
Authors‘ workplace: Klinika otorinolaryngológie, FN Nitra 1;  Klinika otorinolaryngológie, chirurgie hlavy a krku LF UK a UNB, Nemocnica sv. Cyrila a Metoda, Bratislava 2;  Biomedicínske centrum SAV, Bratislava 3
Published in: AtheroRev 2020; 5(1): 22-24
Category:

Overview

Hypercholesterolemia and hearing loss belong to the most prevalent disorders in adult population. It is believed that hypercholesterolemia may contribute to hearing loss. More interestingly, statins were shown to have protective effect on hearing. The exact pathological mechanism how hypercholesterolemia may induce hearing impairment remains unclear. Chronic hypercholesterolemia may lead to glycogen accumulation inside the cochlea and cause edema in the region of the striae vascularis and cochlear outer hair cells. Vascular occlusion has also been suggested as a possible mechanism resulting in hearing loss. Moreover, increased lipid deposition in the inner ear was considered as an alternative mechanism that may induce hearing impairment. To date, literature review on the role of hypercholesterolemia in sensorineural hearing loss provides inconclusive results and limited evidence.

Keywords:

statins – hearing thresholds – Hypercholesterolemia

Sources
  1. Shargorodsky J, Curhan SG, Eavey R et al. A prospective study of cardiovascular risk factors and incident hearing loss in men. Laryngoscope 2010; 120(9): 1887–1891. Dostupné z DOI: <http://dx.doi.org/10.1002/lary.21039>.
  2. Rosen S, Olin P. Hearing loss and coronary heart disease. Arch Otolaryngol 1965; 82: 236–243. Dostupné z DOI: <http://dx.doi.org/10.1001/archotol.1965.00760010238004>.
  3. Evans MB, Tonini R, Shope CD et al. Dyslipidemia and auditory function. Otol Neurotol 2006; 27(5): 609–614. Dostupné z DOI: <http://dx.doi.org/10.1097/01.mao.0000226286.19295.34>.
  4. Oylumlu M, Lolan F, Suleyman E et al. Hearing loss due to familial hypercholesterolemia and statin treatment. Eur J Cardiovasc Med 2013; 2(4): 224–225. Dostupné z DOI: <http://dx.doi.org/10.5083/ejcm.20424884.104>.
  5. Chang IJ, Kang CJ, Yueh CY et al. The relationship between serum lipids and sudden sensorineural hearing loss: A systematic review and metaanalysis. Plos One 2015; 10(4): e0121025. Dostupné z DOI: <http://dx.doi.org/10.1371/journal.pone.0121025>.
  6. Lin HC, Chao PZ, Lee HC. Sudden sensorineural hearing loss increases the risk of stroke: a 5-year follow-up study. Stroke 2008; 39(10): 2744–2748. Dostupné z DOI: <http://dx.doi.org/10.1161/STROKEAHA.108.519090>.
  7. Swaminathan A, Sambandam R, Bhaskaran M. Evaluation of the auditory effects of hyperlipidaemia and diabetes mellitus by using audiometry. J Clin Diagn Res 2011; 5(8), 1528–1532.
  8. Suzuki K, Kaneko M, Murai K. Influence of serum lipids on auditory function. Laryngoscope 2000; 110(10 Pt 1): 1736–1738. Dostupné z DOI: <http://dx.doi.org/10.1097/00005537–200010000–00033>.
  9. Chang SL, Hsieh CC, Tseng KS et al. Hypercholesterolemia is correlated with an increased risk of idiopathic sudden sensorineural hearing loss: A historical prospective cohort study. Ear Hear 2014; 35(2): 256–261. Dostupné z DOI: <http://dx.doi.org/10.1097/AUD.0b013e3182a76637>.
  10. Lin HC, Wang CH, Chou YC et al. The correlation between lipoprotein ratios and hearing outcome in idiopathic sudden sensorineural hearing loss patients. Clin Otolaryngol 2015; 40(4): 355–362. Dostupné z DOI: <http://dx.doi.org/10.1111/coa.12382>.
  11. Deepika P, Rajeshwary A, Usha S et al. Does dyslipidemia worsen the hearing level in diabetics? J Otol 2017; 12(4): 198–201. Dostupné z DOI: <http://dx.doi.org/10.1016/j.joto.2017.07.003>.
  12. Kim DH, Seon-Ki Park SK, Kim KM et al. Association between hearing loss and dyslipidemia prevalence and treatment in adults in Korea: The fifth Korean National Health and Nutrition Examination Survey in 2010? 2012. Korean J Fam Pract (KJPF) 2016; 6(4): 235–241. Dostupné z DOI: <https://doi.org/10.21215/kjfp.2016.6.4.235>.
  13. Xing G, Yao J, Wu B et al. Identification of OSBPL2 as a novel candidate gene for progressive nonsyndromic hearing loss by whole-exome sequencing. Genet Med 2015; 17(3): 210–218. Dostupné z DOI: <http://dx.doi.org/10.1038/gim.2014.90>.
  14. Yao J, Zeng H, Zhang M et al. OSBPL2-disrupted pigs recapitulate dual features of human hearing loss and hypercholesterolaemia. J Genet Genomics 2019; 46(8): 379–387. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jgg.2019.06.006>.
  15. Sirotiaková J. Prehľad liekových interakcií a rizík statínovej liečby. AtheroRev 2017; 2(1): 10–14.
  16. Chung SD, Chen CH, Hung SH et al. A population-based study on the association between statin use and sudden sensorineural hearing loss. Otolaryngol Head Neck Surg 2015; 152(2): 319–325. Dostupné z DOI: <http://dx.doi.org/10.1177/0194599814559382>.
  17. Choo OS, Yoon D, Choi Y et al. Drugs for hyperlipidaemia may slow down the progression of hearing loss in the elderly: A drug repurposing study. Basic Clin Pharmacol Toxicol 2019; 124(4): 423–430. Dostupné z DOI: <http://dx.doi.org/10.1111/bcpt.13150>.
  18. Yücel H, Yücel A, Arbağ H et al. Effect of statins on hearing function and subjective tinnitus in hyperlipidemic patients. Rom J Intern Med 2018; 57(2): 133–140. Dostupné z DOI: <http://dx.doi.org/10.2478/rjim-2018–0035>.
  19. Liu M, Alafris A, Longo AJ et al. Irreversible atorvastatin-associated hearing loss. Pharmacotherapy 2012; 32(2): 27–34. Dostupné z DOI: <http://dx.doi.org/10.1002/PHAR.1040>.
  20. Prayuenyong P, Kasbekar AV, Baguley DM. The efficacy of statins as otoprotective agents: A systematic review. Clin Otolaryngol 2020; 45(1): 21–31. Dostupné z DOI: <http://dx.doi.org/10.1111/coa.13457>.
Labels
Angiology Diabetology Internal medicine Cardiology General practitioner for adults
Editorial
Editorial
Homocysteine consensus
Comments on the new recommendations for dyslipidemia and cardiovascular risk management with regard to diabetes mellitus
Uric acid and influence of hyperuricaemia therapy on prevention of atheroscleroris and cardiovascular diseases
Insulin resistance and atherosclerosis: implications for insulin-sensitizing agents
Pitfalls of diet therapy in dyslipidemias
ASCOT Legacy: the first long-term monitoring of the effect of antihypertensive treatment combined with statin on mortality
Characteristics of patients with uncontrolled arterial hypertension and/or dyslipidemia in primary care in Czechia– LipitenCliDec Study: 1st phase results
Horúce novinky zo štúdie ODYSSEY OUTCOMES (kongres American Heart Association november 2019)
Rešerše zajímavých článků ze zahraniční literatury
Zprávy z odborných akcí ČSAT
Article was published in

Athero Review

Issue 1
2020 Issue 1
Most read in this issue
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#